Shalabh Gupta, MD @shalabhguptamd profile

Shalabh Gupta, MD

@shalabhguptamd

Followers

405

Following

4

Statuses

36

Biotech Entrepreneur - focused on innovation previously board-certified MD, equity research analyst on Wall Street, ex-Genentech, board & advisors to start-ups

San Francisco Bay Area

Joined June 2009

Don't wanna be here? Send us removal request.

Shalabh Gupta, MD

@shalabhguptamd

6 months

Thanks to the team @unicycive

Unicycive Therapeutics

@unicycive

6 months

#Unicycive announced their Q2 #Financials today and provided a corporate update. You can read more about our tremendous progress here:

1

0

3

Shalabh Gupta, MD

@shalabhguptamd

2 years

@b2idigital @unicycive Thank you @b2idigital

0

1

Shalabh Gupta, MD

@shalabhguptamd

2 years

RT @davidshapiroNYC: The entire team at @b2idigital is proud to welcome @unicycive Therapeutics, Inc. (NASDAQ: $UNCY) as a new member of ou…

0

1

0

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting

6

0

7

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway On-track to submit New Drug Application in Q4 2022

0

2

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021

0

2

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Therapeutics Appoints Douglas Jermasek as Executive Vice President, Corporate Strategy

0

1

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Therapeutics to be Added to Russell Microcap® Index

0

2

Shalabh Gupta, MD

@shalabhguptamd

3 years

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

0

Shalabh Gupta, MD

@shalabhguptamd

4 years

Unicycive Therapeutics Announces Pricing of Initial Public Offering

0

Shalabh Gupta, MD

@shalabhguptamd

4 years

Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease

0

Shalabh Gupta, MD

@shalabhguptamd

5 years

Keith Ward, Ph.D. Joins as the Chief Development Officer of Unicycive

1

0

1

Shalabh Gupta, MD

@shalabhguptamd

5 years

@keithwward Dr. Keith Ward joins our team at Unicycive as Chief Development Officer. His experience in Reata and Bausch & Lomb will be helpful to advance our drugs. Kidney patients need new treatments, together we can make a difference.

0

Shalabh Gupta, MD

@shalabhguptamd

5 years

RT @ps_onlyconnect: This one thing about which I am not the least uncertain.

0

1

0

Shalabh Gupta, MD

@shalabhguptamd

5 years

RT @bradloncar: Of all the bio industry reforms that are happening in China right now, the reimbursement of innovative medicines is by far…

0

9

0

Shalabh Gupta, MD

@shalabhguptamd

6 years

RT @dbsable: A few words about Michael. @Becker_MichaelD

0

12

0

Shalabh Gupta, MD

@shalabhguptamd

7 years

Congrats on both fronts - 1. New treatment for AML patients, and 2. To the team at AGIO for such a great success.

Robert Nelsen

@rtnarch

7 years

Congrats to Agios (AGIO) for approval of its second drug for AML (TIBSOVO). Fastest ever approval of distinct drugs for two independent mechanisms. First company to have two drugs with internally discovered pathways in a decade from start. ARCH named it and seeded with Flagship.

0

2

Shalabh Gupta, MD

@shalabhguptamd

7 years

Excited about @Globavir collaboration with @SingHealthSG

1

0

Shalabh Gupta, MD

@shalabhguptamd

7 years

@Globavir excited to share our collaboration with @SingHealthSG

0

Shalabh Gupta, MD

@shalabhguptamd

8 years

Very well written article --America’s ‘Miracle Machine’ is in desperate need of, well, a miracle

0